Resona Asset Management Co. Ltd. Sells 5,371 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Resona Asset Management Co. Ltd. reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 34,328 shares of the biopharmaceutical company’s stock after selling 5,371 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $19,294,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Marino Stram & Associates LLC grew its position in Regeneron Pharmaceuticals by 5.3% in the second quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 20 shares in the last quarter. CoreCap Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 9.2% in the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 20 shares during the last quarter. Strait & Sound Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 3.5% in the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock worth $353,000 after purchasing an additional 21 shares during the period. Parkside Financial Bank & Trust increased its position in shares of Regeneron Pharmaceuticals by 14.8% during the 3rd quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 21 shares during the last quarter. Finally, CX Institutional raised its holdings in Regeneron Pharmaceuticals by 7.9% during the 2nd quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 22 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on REGN. Cantor Fitzgerald lifted their price objective on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Evercore ISI lifted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research note on Thursday. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research note on Thursday, December 4th. Finally, Wells Fargo & Company upped their target price on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a research note on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $794.70.

Insider Activity

In related news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 8,431 shares of company stock worth $5,733,521. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $753.55 on Friday. The company has a market capitalization of $79.20 billion, a P/E ratio of 18.04, a P/E/G ratio of 1.96 and a beta of 0.39. The company’s 50-day simple moving average is $755.38 and its two-hundred day simple moving average is $643.73. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same quarter in the previous year, the business earned $12.46 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up .9% on a year-over-year basis. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Seeking Alpha previews Regeneron’s Q4 and expects an earnings beat and a strong 2026, maintaining a Buy rating and noting the shares have rallied >16% since the author’s prior note — this supports upside if results meet or exceed guidance. Read More.
• Positive Sentiment: Zacks says Regeneron has the right setup to beat upcoming earnings (Earnings “ESP”/estimates upside), which could trigger further upside if the company reports above-consensus results. Read More.
• Positive Sentiment: Evercore ISI raised its price target on REGN from $750 to $875 and kept an “outperform” call — a material analyst upgrade that increases implied upside and can support buying interest. Read More.
• Positive Sentiment: MarketBeat aggregation (reported on DefenseWorld/American Banking News) shows an average analyst rating of “Moderate Buy” across ~28 brokerages, indicating broad analyst conviction that could limit downside absent a negative print. Read More.
• Neutral Sentiment: Reminders that Regeneron will release quarterly earnings on Friday — serves as the immediate event risk/reward driver; expect heightened volume and larger intraday moves around the report. Read More.
• Neutral Sentiment: Zacks compares REGN with Illumina (ILMN) on valuation — useful context for investors weighing sector alternatives, but not an immediate catalyst for REGN alone. Read More.
• Neutral Sentiment: A Zacks piece highlights two medical names that could beat earnings (including REGN), which reinforces market attention on earnings-season upside but is not new company-specific data. Read More.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.